Oral calcidiol is more effective than cholecalciferol supplementation to reach adequate 25(oh)d levels in patients with autoimmune diseases chronically treated with low doses of glucocorticoids: A "real-life" study

Journal of Osteoporosis

Volumn 2015, Issue , 2015, Pages

  Ortego Jurado, Miguel ^a   Callejas Rubio, José Luis ^b   Ríos Fernández, Raquel ^b   González Moreno, Juan ^a   González Ramírez, Amanda Rocío ^c   González Gay, Miguel A ^d   Ortego Centeno, Norberto ^b  

^a HOSPITAL SON LLÀTZER   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCIFEDIOL; COLECALCIFEROL; GLUCOCORTICOID;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BODY MASS; CORTICOSTEROID THERAPY; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALE; MYOSITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SYSTEMIC VASCULITIS; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 84934999752     PISSN: 20908059     EISSN: 20420064     Source Type: Journal    
DOI: 10.1155/2015/729451     Document Type: Article

References (34)

1. C. M. Spies, C. Strehl, M. C. Van Der Goes, J. W. J. Bijlsma, and F. Buttgereit, "Glucocorticoids," Best Practice and Research: Clinical Rheumatology, vol. 25, no. 6, pp. 891-900, 2011
2. R. S. Weinstein, "Clinical practice: glucocorticoid-induced bone disease,"TheNewEngland Journal ofMedicine, vol. 365, no. 1, pp. 62-70, 2011
3. J. M. Grossman, R. Gordon, V. K. Ranganath et al., "American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis," Arthritis Care & Research, vol. 62, no. 11, pp. 1515-1526, 2010
4. K. Briot, B. Cortet, C. Roux et al., "2014 update of recommendations on the prevention and treatment of glucocorticoidinduced osteoporosis," Joint Bone Spine, vol. 81, no. 6, pp. 493-501, 2014
5. M. Ishijima, Y. Sakamoto, M. Yamanaka et al., "Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women," Calcified Tissue International, vol. 85, no. 5, pp. 398-404, 2009
6. A. S. Carmel, A. Shieh, H. Bang, and R. S. Bockman, "The 25(OH)D level needed to maintain a favorable bisphosphonate response is ?33 ng/ml," Osteoporosis International, vol. 23, no. 10, pp. 2479-2487, 2012
7. P. Peris, A. Mart?nez-Ferrer, A. Monegal, M. J. Mart?nez de Osaba, A. Muxi, and N. Guanabens, "25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis," Bone, vol. 51, no. 1, pp. 54-58, 2012
8. M. Ortego-Jurado, R. R?os-Fernandez, J. L. Callejas-Rubio, M. A. Gonzalez-Gay, and N. Ortego-Centeno, "Vitamin D levels and response to biphosphonates in postmenopausal women receiving glucocorticoid therapy," Osteoporosis International, vol. 25, pp. 2157-2158, 2014
9. S. Mazzaferro, D. Goldsmith, T. E. Larsson, Z. A. Massy, and M. Cozzolino, "VitaminDmetabolites and/or analogs: whichDfor which patient?" Current Vascular Pharmacology, vol. 12, no. 2, pp. 339-349, 2014
10. A. Jetter, A. Egli, B. Dawson-Hughes et al., "Pharmacokinetics of oral vitamin D3 and calcifediol," Bone, vol. 59, pp. 14-19, 2014
11. R. P. Heaney, "Thenutrient problem," Nutrition Reviews, vol. 70, no. 3, pp. 165-169, 2012
12. R. Bouillon, N.M. vanSchoor, E. Gielen et al., "Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine," Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 8, pp. E1283-E1304, 2013
13. A. Deane, L. Constancio, I. Fogelman, and G. Hampson, "The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-termuse in post-menopausal osteoporosis," BMC Musculoskeletal Disorders, vol. 8, article 3, 2007
14. R. Vieth, "Why the minimum desirable serum 25-hydroxyvitamin D level should be 75 nmol/L (30 ng/ml)," Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 25, no. 4, pp. 681-691, 2011
15. P. Mezquita Raya, M. Munoz Torres, F. Lopez Rodr?guez et al., "Prevalence of vitamin D deficiency in populations at risk for osteoporosis: impact on bone integrity," Medicina Clinica, vol. 119, no. 3, pp. 85-89, 2002
16. C. Lopez-Robles, R. Rios-Fernandez, J. L. Callejas-Rubio, and N. Ortego-Centeno, "Vitamin D deficiency in a cohort of patients with systemic lupus erythematous from the South of Spain," Lupus, vol. 20, no. 3, pp. 330-331, 2011
17. R. Rios-Fernandez, J. L. Callejas-Rubio, C. Fernandez-Roldan et al., "Bone mass and vitamin D in patients with systemic sclerosis from two Spanish regions," Clinical and Experimental Rheumatology, vol. 30, pp. 905-911, 2012
18. P. Saneei, A. Salehi-Abargouei, and A. Esmaillzadeh, "Serum 25-hydroxy vitamin D levels in relation to body mass index: a systematic review and meta-Analysis," Obesity Reviews, vol. 14, no. 5, pp. 393-404, 2013
19. T. J. Hahn, L. R. Halstead, and J. G. Haddad Jr., "Serum 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid therapy," Journal of Laboratory and Clinical Medicine, vol. 90, no. 2, pp. 399-404, 1977
20. D. M. Slovik, R. M. Neer, J. L. Ohman et al., "Parathyroid hormone and 25-hydroxyvitamin D levels in glucocorticoidtreated patients," Clinical Endocrinology, vol. 12, no. 3, pp. 243-248, 1980
21. Z. E. Davidson, K. Z. Walker, and H. Truby, "Do glucocorticosteroids alter vitamin D status? A systematic review with meta-Analyses of observational studies," Journal of Clinical Endocrinology andMetabolism, vol. 97, no. 3, pp. 738-744, 2012
22. A. L. Skversky, J. Kumar, M. K. Abramowitz, F. J. Kaskel, and M. L. Melamed, "Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and Nutrition Examination Survey (NHANES): 2001-2006," The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 12, pp. 3838-3845, 2011
23. N. Akeno, A. Matsunuma, T. Maeda, T. Kawane, and N. Horiuchi, "Regulation of vitamin D-1-hydroxylase and-24-hydroxylase expression by dexamethasone in mouse kidney," Journal of Endocrinology, vol. 164, no. 3, pp. 339-348, 2000
24. I. Kurahashi, A. Matsunuma, T. Kawane, M. Abe, and N. Horiuchi, "Dexamethasone enhances vitamin D-24-hydroxylase expression in osteoblastic (UMR-106) and renal (LLC-PK1) cells treatedwith 1alpha, 25-dihydroxyvitamin D3," Endocrine, vol. 17, no. 2, pp. 109-118, 2002
25. P. Dhawan and S. Christakos, "Novel regulation of 25-hydroxyvitamin D3 24-hydroxylase (24(OH)ase) transcription by glucocorticoids: cooperative effects of the glucocorticoid receptor, C/EBP, and the vitamin D receptor in 24(OH)ase transcription," Journal of Cellular Biochemistry, vol. 110, no. 6, pp. 1314-1323, 2010
26. A. V. Khomenko, "Cholecalciferol hydroxylation in rat hepatocytes under the influence of prednisolone," Ukrainski Biokhimicheski Zhurnal, vol. 85, no. 3, pp. 90-95, 2013
27. I. Garcia-Delgado, S. Prieto, L. Gil-Fraguas, E. Robles, J. J. Rufilanchas, and F. Hawkins, "Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation," Calcified Tissue International, vol. 60, no. 2, pp. 155-159, 1997
28. M. Talalaj, L. Gradowska, E. Marcinowska-Suchowierska, M. Durlik, Z. Gaciong, and M. Lao, "Efficiency of preventive treatment of glucocorticoid-induced osteoporosis with 25-hydroxyvitamin D3 and calcium in kidney transplant patients," Transplantation Proceedings, vol. 28, no. 6, pp. 3485-3487, 1996.
29. H. A. Bischoff-Ferrari, B. Dawson-Hughes, E. Stocklin et al., "Oral supplementation with 25(OH)D3 versus vitamin D3: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity," Journal of Bone and Mineral Research, vol. 27, no. 1, pp. 160-169, 2012
30. K. D. Cashman, K. M. Seamans, A. J. Lucey et al., "Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raisingwintertime serum25-hydroxyvitaminDin older adults," The American Journal of Clinical Nutrition, vol. 95, no. 6, pp. 1350-1356, 2012
31. T. C. B. Stamp, "Intestinal absorption of 25 hydroxycholecalciferol," The Lancet, vol. 2, no. 7873, pp. 121-123, 1974
32. L. Cianferotti, C. Cricelli, J. A. Kanis et al., "The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF)," Endocrine, 2015
33. D. Price, A. Chisholm, T. van der Molen, N. Roche, E. V. Hillyer, and J. Bousquet, "Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness," Current Allergy and Asthma Reports, vol. 11, no. 6, pp. 526-538, 2011
34. A. I. R. Garcia, "Recommendations on vitamin D and calcium supplements for adults in Spain," Revista Espanola de Salud Publica, vol. 86, no. 5, pp. 461-482, 2012